Ovarian Cancer

Folate receptor alpha was a promising biomarker when it came to treatment with mirvetuximab soravtansine.

A recent review of data found that 79 percent of patients with ovarian cancer felt uncomfortable raising psychological and emotional concerns during their consultations.

In the QUADRA study, treatment with Zejula (niraparib) demonstrated durable responses among women with relapsed or refractory ovarian cancer, regardless of BRCA mutation.

Lynch syndrome – a hereditary condition that increases a person’s risk for developing several types of cancer – is common among people with microsatellite instability-high (MSI-H) tumors, linking it to several new cancer types, according to large genomic study results presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

The Food and Drug Administration approved a combination of Avastin (bevacizumab) plus the chemotherapy agents carboplatin and paclitaxel, followed by Avastin alone, for the treatment of patients with advanced ovarian cancer who have had surgical resection.

The FDA approved the Paxman Scalp Cooling System for patients with solid tumors who wish to prevent chemotherapy-related hair loss.

Although genetic testing could be crucial in developing treatment plans and improving outcomes in women with ovarian and breast cancer, less than 20 percent of eligible patients actually get tested, according to Mike Janicek, M.D.

The field of ovarian cancer is changing rapidly, and moving toward an era of precision medicine.

While many advocacy groups set out to raise money for cancer research, a first-of-its-kind charitable crowdfunding platform, called Sound Affects, has set out to change how the war on cancer is fought and financed, all with support from musical talents.

There are now three PARP inhibitors approved for the treatment of ovarian cancer, improving outcomes of many of the women who take them.

Paradigms are shifting in the way that ovarian cancer is being treated.

Memorial Day has multiple meanings for this cancer survivor.

Survivors teach medical and nursing students around the world about early disease signs and symptoms.

Girls Gone Rx sponsors all-female fitness competitions to raise money for Bright Pink, a nonprofit that focuses on prevention and early detection of breast and ovarian cancer.

Palliative care can be used at all cancer stages, and can drastically improve patients' quality of life.

With the number of treatment options consistently increasing, tumor testing is growing more important to personalize care for women with ovarian cancer.

An evening of storytelling among women afflicted by ovarian cancer – whether it be their own diagnosis or a loved one’s – helped to empower individuals to find their voice.

Hear from our four Ovarian Cancer Heroes about what inspires them in the fight against the disease.

So, what was the first thing I thought about when I vowed to not think about cancer? Cancer, of course.

The Food and Drug Administration (FDA) approved a next-generation sequencing (NGS) companion diagnostic assay that can detect BRCA1/2 genetic mutations, as well as the percentage of genomic loss of heterozygosity (LOH) in patients with ovarian cancer.

Albeit growing popularity of at-home genetic testing, it is still necessary to seek professional medical opinions from genetic counselors to help discuss results.

Many patients with ovarian cancer have misconceptions about the care they will receive while on a clinical trial, according to Laurel W. Rice, M.D.

Yoga and Reiki can have great benefits for patients undergoing cancer treatment, according to Patrick Dempsey.

Patrick Dempsey, actor, cancer advocate and Breakaway From Cancer® Ambassador, sat down with CURE® to discuss how cancer impacted his life after his mother was diagnosed with ovarian cancer.

Cancer is a serious business. But who said it needs to be a business of seriousness?

PARP inhibitors are continuing to create buzz in the ovarian cancer space, both as single agents and in combinations that are currently being examined in clinical trials.

The Food and Drug Administration (FDA) approved Rubraca (rucaparib) as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, according to Clovis Oncology, the company that manufactures the drug.

Despite exciting developments of PARP inhibitors over the years, limited knowledge exists in the mechanism of PARP-7 and its potential effect in targeted therapy for patients with ovarian cancer.

Following fertility clinic malfunctions in Cleveland and San Francisco, many patients who have or had cancer are facing devastating losses, leaving many questions in the wake of these events.